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Abstract
Background Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients
with moderate-to-severe psoriasis.
Objective Evaluate efficacy and safety of apremilast vs. placebo in biologic-naive patients with moderate-to-severe
plaque psoriasis and safety of switching from etanercept to apremilast in a phase IIIb, randomized, double-blind, pla-
cebo-controlled study (NCT01690299).
Methods Two hundred and fifty patients were randomized to placebo (n = 84), apremilast 30 mg BID (n = 83) or etan-
ercept 50 mg QW (n = 83) through Week 16; thereafter, all patients continued or switched to apremilast through Week
104. The primary efficacy endpoint was achievement of PASI-75 at Week 16 with apremilast vs. placebo. Secondary
endpoints included achievement of PASI-75 at Week 16 with etanercept vs. placebo and improvements in other clinical
endpoints vs. placebo at Week 16. Outcomes were assessed through Week 52. This study was not designed for
apremilast vs. etanercept comparisons.
Results At Week 16, PASI-75 achievement was greater with apremilast (39.8%) vs. placebo (11.9%; P < 0.0001);
48.2% of patients achieved PASI-75 with etanercept (P < 0.0001 vs. placebo). PASI-75 response was maintained in
47.3% (apremilast/apremilast), 49.4% (etanercept/apremilast) and 47.9% (placebo/apremilast) of patients at Week 52.
Most common adverse events (≥5%) with apremilast, including nausea, diarrhoea, upper respiratory tract infection,
nasopharyngitis, tension headache and headache, were mild or moderate in severity; diarrhoea and nausea generally
resolved in the first month. No new safety or tolerability issues were observed through Week 52 with apremilast.
Conclusion Apremilast demonstrated significant efficacy vs. placebo at Week 16 in biologic-naive patients with psori-
asis, which was sustained over 52 weeks, and demonstrated safety consistent with the known safety profile of
apremilast. Switching from etanercept to apremilast did not result in any new or clinically significant safety findings, and
efficacy was maintained with apremilast through Week 52.
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Introduction
Psoriasis is a chronic, systemic inflammatory disease marked by
overproduction of pro-inflammatory mediators.1,2 Early treat-
ment with effective agents that target the pathophysiologic path-
ways of psoriasis and have improved safety profiles is needed for
long-term treatment of patients with chronic plaque psoriasis.3
Apremilast, an oral small-molecule phosphodiesterase 4 (PDE4)
inhibitor, works intracellularly to regulate inflammatory media-
tors, including pathways relevant to the pathogenesis of psoria-
sis.4,5 PDE4 inhibition elevates cyclic adenosine monophosphate
levels, which downregulates inflammatory responses and upreg-
ulates production of anti-inflammatory cytokines.5,6 Apremilast
has demonstrated clinically meaningful improvements in the
treatment of psoriatic arthritis in patients with active disease in
the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy
(PALACE) phase III clinical trial programme (PALACE 1
[NCT01172938]; PALACE 2 [NCT01212757]; PALACE 3
[NCT01212770]).7–9 The efficacy and safety of apremilast in
patients with moderate-to-severe plaque psoriasis who were can-
didates for phototherapy or systemic therapy have been demon-
strated in the global, phase III placebo-controlled Efficacy and
Safety Trial Evaluating the Effects of Apremilast in Psoriasis clin-
ical trial programme (ESTEEM 1 [NCT01194219] and ESTEEM
2 [NCT01232283]).10,11
Here, we report the findings from a phase IIIb study (Evalua-
tion in a Placebo-Controlled Study of Oral Apremilast and Etan-
ercept in Plaque Psoriasis [LIBERATE]) that evaluated
apremilast vs. placebo at Week 16 in biologic-naive patients with
moderate-to-severe plaque psoriasis. The study also included an
active control arm that investigated the efficacy of etanercept
50 mg subcutaneous injection QW vs. placebo at Week 16 and
the relative safety of switching from etanercept to apremilast at
Week 16 as compared with uninterrupted apremilast through
Week 52. The study was not designed or powered to make direct
comparisons between apremilast and etanercept, and compar-
ison of the efficacy and safety of the two active arms was not a
pre-specified objective of the trial. In contrast to the ESTEEM
trials, the current study did not include a randomized with-
drawal phase by Psoriasis Area and Severity Index (PASI)
response at Week 32, allowing assessment of the efficacy of long-
term uninterrupted apremilast treatment through Week 52.
Additionally, in the ESTEEM trials, up to one-third of patients
had received prior biologic therapy.10,11
Materials and methods
LIBERATE was a global, phase IIIb, multi-centre, randomized,
double-blind, placebo-controlled study (NCT01690299).
Patients provided written informed consent. The protocol and
consent were approved by institutional review boards or ethics
committees for all investigational sites. The study was conducted
in accordance with the principles of Good Clinical Practice and
the Declaration of Helsinki.
Study population
Adult patients aged ≥18 years were eligible if they had chronic
plaque psoriasis for ≥12 months (PASI score ≥12, affected body
surface area [BSA] ≥10%, static Physician Global Assessment
[sPGA] score ≥3 [moderate to severe]); inadequate response,
intolerance or contraindication to ≥1 conventional systemic
agent for treatment of psoriasis; were candidates for photother-
apy or systemic (including etanercept) therapy; and had no prior
exposure to a biologic therapy for psoriasis or psoriatic arthritis.
Excluded patients included those with prior failure of >3 sys-
temic agents for treatment of psoriasis; history of known
demyelinating diseases such as multiple sclerosis or optic neuri-
tis or history of or concurrent congestive heart failure, including
medically controlled, asymptomatic congestive heart failure;
other clinically significant or major uncontrolled disease; serious
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infection; latent, active or history of incompletely treated tuber-
culosis.
Permitted concomitant medications
Low-potency topical corticosteroids as background therapy for
treatment of face, axillae and groin psoriasis lesions, coal tar
shampoo and/or salicylic acid scalp preparations for scalp lesions
and non-medicated emollients for body lesions were permitted
except within 24 h before study visits.
Study design
Eligible patients were randomized (1 : 1 : 1) via an interactive
voice response system to placebo; apremilast oral tablet, 30 mg
BID; or etanercept subcutaneous injection, 50 mg QW (placebo-
controlled phase; Fig. 1). Patients were stratified by screening
body mass index (BMI; <30 and ≥30 kg/m2). Per the double-
dummy design, patients received oral tablets (apremilast 30 mg
or placebo) BID and two subcutaneous injections (etanercept
25 mg each dose or saline placebo) QW. Apremilast was dose-
titrated over the first week of treatment. At Week 16, placebo
and etanercept patients were switched to apremilast 30 mg BID:
placebo without apremilast titration (placebo/apremilast) and
etanercept with apremilast titration (etanercept/apremilast).
Apremilast patients continued receiving apremilast (apremilast/
apremilast). All patients maintained this dosing from Weeks 16
to 104 (apremilast-extension phase). Blinding was maintained
throughout the trial until all patients discontinued or completed
the Week 104 visit. At Week 32, patients who did not achieve a
≥50% reduction from baseline in PASI score (PASI-50) could
add topical therapy including but not limited to topical corticos-
teroids, topical retinoids or vitamin D analogues and/or UVB
phototherapy, based on investigator discretion.
Assessments
The primary efficacy endpoint was the proportion of patients
who achieved a ≥75% reduction from baseline in PASI score
(PASI-75) at Week 16 with apremilast or placebo. A secondary
efficacy endpoint was the proportion of patients treated with
etanercept or placebo who achieved PASI-75 at Week 16. Safety
assessments included collection of adverse events (AEs), vital
signs, clinical laboratory testing, physical examination, chest
radiograph and 12-lead electrocardiogram.
Statistical analysis
Efficacy assessments were conducted for the modified intent-to-
treat (mITT) population (all randomized patients who received
≥1 dose of study medication and had both baseline PASI and ≥1
post-treatment PASI evaluations). The safety population con-
sisted of all patients who were randomized and received ≥1 dose
of study medication. Approximately 240 patients were planned
to be randomized, to yield 90% power to detect a difference of
20 percentage points between apremilast and placebo for pro-
portions of patients achieving PASI-75 at Week 16 (primary
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Figure 1 LIBERATE Study Design. *Starting at Week 32, all non-responders (<PASI-50) had the option of adding topical therapies and/
or ultraviolet B phototherapy (excluding oral psoralen combined with ultraviolet A) to their treatment regimen. Two patients in each group
received topical therapy and/or phototherapy. PASI-50, 50% or greater reduction from baseline in Psoriasis Area and Severity Index
score.
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etanercept comparisons; a post hoc comparison yielded a calcu-
lated power of 19% for detecting the observed difference. Multi-
plicity control of statistical testing was conducted in a
hierarchical manner for secondary endpoints at Week 16 to con-
trol the overall type I error rate. Continuous endpoints were
evaluated using an analysis of covariance model with treatment
and baseline BMI (<30 and ≥30 kg/m2) as factors and baseline
value as a covariate. Last-observation-carried-forward (LOCF)
methodology was used to impute missing efficacy measure-
ments. Multiple sensitivity analyses (including non-responder
imputation) were conducted for the primary (PASI-75 at Week
16) and select secondary (PASI-50 and sPGA score 0 [clear] or 1
[almost clear] with a ≥2-point reduction from baseline at Week
16) endpoints. Safety data were summarized using descriptive
statistics for the placebo-controlled phase (Weeks 0 to 16) and
the apremilast-extension phase (Weeks 16 to 52).
Results
Patients
A total of 250 patients were randomized and included in the full
analysis set (placebo, n = 84; apremilast, n = 83; etanercept,
n = 83). Of these patients, 233 completed the placebo-controlled
phase (Weeks 0 to 16) (Fig. 2). A total of 226 patients (placebo/
apremilast, n = 73; apremilast/apremilast, n = 74; etanercept/
apremilast, n = 79) entered the apremilast-extension phase
(Weeks 16 to 52) and received ≥ 1 dose of study medication.
Overall, 181 patients received treatment through Week 52.
Apremilast-extension phase (Weeks 16 to 52)
Placebo-controlled phase (Weeks 0 to 16)
350 patients screened




Discontinued, n = 2 Discontinued, n = 2 
         
81 completed placebo-
controlled phase
Discontinued, n = 3
Apremilast 30 mg BID
n = 83
Placebo
n = 84 
Etanercept 50 mg QW
n = 83
Discontinued, n = 9
   • 2 had adverse events
   • 4 lack of efficacy
   • 1 withdrew consent
   • 2 for other reasons
Discontinued, n = 6
   • 2 had adverse events
   • 3 withdrew consent
   • 1 for other reasons
Discontinued, n = 2
   • 1 had adverse events









79 switched to 
apremilast
Discontinued, n = 18
     • 1 had adverse events
     • 8 lack of efficacy
     • 2 withdrew consent
     • 7 lost to follow-up
Discontinued, n = 13
• 2 had adverse events
    • 3 lack of efficacy
    • 4 withdrew consent
    • 3 lost to follow-up
    • 1 protocol violation
 Discontinued, n = 14
• 3 had adverse events
      • 2 lack of efficacy
      • 5 withdrew consent
      • 3 lost to follow-up
      • 1 for other reasons
56 completed Week 52 visit 66 completed Week 52 visit59 completed Week 52 visit
apremilast
Figure 2 Patient Disposition.
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Demographic and baseline characteristics were generally bal-
anced between groups (Table 1); mean psoriasis duration at
baseline was 18.2 years, and mean PASI score was 19.6.
Efficacy
Weeks 0 to 16 At Week 16, PASI-75 response was achieved by
significantly more patients receiving apremilast (39.8%) vs. pla-
cebo (11.9%, P < 0.0001; Fig. 3 and Table 2). At Week 16, PASI-
75 response was achieved by significantly more patients receiving
etanercept (48.2%) vs. placebo (11.9%, P < 0.0001; Fig. 3 and
Table 2). Results of the non-responder imputation sensitivity
analyses were similar to those of the primary analysis (Table 2).
Significant improvements were achieved with apremilast (vs.
placebo) at Week 16 for the following secondary endpoints:
sPGA score of 0 (clear) or 1 (almost clear), percentage change
from baseline in the psoriasis affected BSA, PASI-50 response,
change from baseline in Dermatology Life Quality Index (DLQI)
total score and Lattice System Physician’s Global Assessment
(LS-PGA) score of 0 (clear) or 1 (almost clear) (Table 2).
Treatment with apremilast or etanercept led to improvements
from baseline at Week 16 (vs. placebo) in exploratory endpoints,
including mean percentage change from baseline in PASI score,
achievement of a minimal clinically important difference
(MCID) in DLQI score (decrease from baseline DLQI score ≥5
points)12,13 and mean change from baseline in pruritus and skin
discomfort/pain visual analogue scale (VAS) scores, Scalp Physi-
cian Global Assessment (ScPGA) response (score of 0 [clear] or
1 [minimal]) and mean percentage change from baseline in Nail
Psoriasis Severity Index (NAPSI) score (Table 2). In a post hoc







Age, mean (SD), years 43.4 (14.9) 46.0 (13.6) 47.0 (14.1)
Male, n (%) 59 (70.2) 49 (59.0) 49 (59.0)
Race, n (%)
White 80 (95.2) 79 (95.2) 75 (90.4)
Asian 2 (2.4) 0 (0.0) 1 (1.2)
Black 1 (1.2) 3 (3.6) 5 (6.0)
Other 1 (1.2) 1 (1.2) 2 (2.4)
Body mass index, mean (SD), kg/m2 29.5 (6.6) 29.2 (5.8) 29.9 (6.8)
Weight, mean (SD), kg 89.5 (23.1) 88.5 (19.8) 88.1 (20.5)
Duration of psoriasis, mean (SD), years 16.6 (12.1) 19.7 (12.7) 18.1 (11.7)
PASI score (0–72), mean (SD) 19.4 (6.8) 19.3 (7.0) 20.3 (7.9)
PASI score >20, n (%) 32 (38.1) 28 (33.7) 34 (41.0)
Body surface area, mean (SD), % 27.3 (16.1) 27.1 (15.6) 28.4 (15.7)
Body surface area >20%, n (%) 42 (50.0) 45 (54.2) 47 (56.6)
sPGA of 4 (severe), n (%) 23 (27.4) 17 (20.5) 13 (15.7)
DLQI score (0–30), mean (SD) 11.4 (6.3) 13.6 (6.7) 12.5 (7.0)
VAS scores (0–100 mm), mean (SD), mm
Pruritus 62.5 (22.7) 62.6 (25.7) 57.2 (27.7)
Skin discomfort/pain 43.9 (31.2) 51.8 (30.8) 47.3 (32.8)
Patient global assessment of psoriasis disease activity 53.6 (21.6) 60.9 (24.6) 55.6 (24.2)
Prior use of conventional systemic medications, n (%) 70 (83.3) 66 (79.5) 58 (69.9)
The n reflects the number of randomized patients; actual number of patients available for each parameter may vary. DLQI, Dermatology Life Quality Index;




































































Figure 3 PASI-75 Response at Week 16 (LOCF) and Week 52
(EOP). *P < 0.0001 vs. placebo. The vertical lines indicate two-
sided 95% CIs. CI, confidence interval; EOP, end of phase; LOCF,
last observation carried forward; for the apremilast-extension
phase, this includes the last observation in the phase, between
Week 16 and Week 52; n/m, number of responders/number of
patients with sufficient data for evaluation; PASI-75, 75% or
greater reduction from baseline in Psoriasis Area and Severity
Index score.
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Table 2 Clinical response across efficacy endpoints at Week 16 and Week 52
Placebo-controlled phase:
Weeks 0 to 16*
Apremilast-extension phase:
















Primary endpoint, n (%)




39 (53.4) 39 (52.7) 45 (57.0)
P = 0.2565 APR vs. ETN (post hoc)




35 (47.9) 35 (47.3) 39 (49.4)
Secondary endpoints




26 (35.6) 18 (24.3) 21 (26.6)




25 (34.2) 16 (21.6) 16 (20.3)
Percentage change from baseline in
psoriasis affected BSA (LOCF), mean (SD)




60.8 (37.2) 58.6 (32.0) 72.0 (22.8)




53 (72.6) 52 (70.3) 72 (91.1)




48 (65.8) 47 (63.5) 61 (77.2)
Change from baseline in total DLQI
score (LOCF), mean (SD)




6.7 (6.1) 8.2 (7.0) 6.9 (7.3)




19 (26.0) 21 (28.4) 19 (24.1)
Exploratory endpoints




19 (26.0) 13 (17.6) 22 (27.8)
Percentage change from baseline in
PASI score (LOCF), mean (SD)




66.3 (32.4) 66.2 (26.7) 75.1 (21.0)
Patients with DLQI >5 at baseline n = 84 n = 83 n = 83 n = 59 n = 66 n = 64
Patients achieving DLQI MCID
(decrease from baseline >=5 points)
(LOCF), n (%)




40 (67.8) 52 (78.8) 43 (67.2)
Change from baseline in pruritus VAS score
(LOCF), mean (SD), mm




35.9 (30.0) 31.7 (30.5) 32.1 (33.1)
Change from baseline in skin discomfort/pain VAS
score (LOCF), mean (SD), mm




21.7 (29.9) 24.9 (37.5) 28.5 (30.9)
Change from baseline in patient global
assessment of psoriasis disease
activity VAS (LOCF), mean (SD), mm




29.3 (30.1) 30.7 (30.8) 32.0 (31.3)
Patients with nail psoriasis at baseline|| n = 42 n = 50 n = 50 n = 37 n = 48 n = 46
Percentage change from baseline in
NAPSI score (LOCF), mean (SD)




51.1 (43.5) 44.6 (44.3) 60.7 (39.7)
Patients with moderate or greater
scalp psoriasis at baseline
n = 58 n = 54 n = 54 n = 50 n = 49 n = 53
ScPGA score 0 (clear) or 1 (minimal)
(LOCF), n (%)




26 (52.0) 26 (53.1) 32 (60.4)
The n reflects the number of randomized patients; actual number of patients available for each parameter may vary.
*Week 16 missing data were handled with LOCF methodology; sensitivity analyses used NRI methodology for missing values.
†Data are from patients who entered and received at least one dose of study medication during the Week 16 to Week 52 apremilast-extension phase; missing
data were handled with LOCF methodology using data from the apremilast-extension phase; sensitivity analyses used NRI methodology for missing values.
‡sPGA score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline; LS-PGA score of 0 (clear) or 1 (almost clear).
||Patients with a baseline value and at least one post-baseline value are included.
Italicized P-values are nominal due to hierarchy of statistical testing of secondary endpoints.
APR, apremilast; BID, twice daily; BSA, body surface area; DLQI, Dermatology Life Quality Index; ETN, etanercept; LOCF, last observation carried forward;
LS-PGA, Lattice System Physician’s Global Assessment; MCID, minimal clinically important difference; NAPSI, Nail Psoriasis Severity Index; NRI, non-
responder imputation; PASI, Psoriasis Area and Severity Index; PASI-50, 50% or greater reduction from baseline in PASI score; PASI-75, 75% or greater
reduction from baseline in PASI score; PASI-90, 90% or greater reduction from baseline in PASI score; sPGA, static Physician Global Assessment (0 = clear,
1 = almost clear, 2 = mild, 3 = moderate, 4 = severe); ScPGA, Scalp Physician Global Assessment; VAS, visual analogue scale.
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analysis (LOCF), 22 of 83 (26.5%) patients receiving apremilast
and 27 of 83 (32.5%) patients receiving etanercept vs. 13 of 84
(15.5%) receiving placebo achieved a DLQI score of 0 or 1 at
Week 16 (Fig. 4).
Improvements in patient-reported VAS scores for pruritus
and skin discomfort/pain occurred as early as Week 2 with
apremilast and etanercept vs. placebo. At Week 16, mean
change from baseline in pruritus VAS was greater with
apremilast and etanercept vs. placebo (Table 2; nominal
P = 0.0026 apremilast vs. placebo, nominal P < 0.0001 etaner-
cept vs. placebo), representing 56.9%, 63.6% and 36.0%
reductions from baseline in mean pruritus VAS scores,
respectively. A post hoc analysis (LOCF) found that an MCID
in pruritus VAS (improvement of ≥20%)14 was achieved by
66 of 83 (79.5%) and 69 of 83 (83.1%) patients receiving
apremilast and etanercept, respectively, vs. 45 of 84 (53.6%)
patients receiving placebo at Week 16.
Results over 52 weeks PASI-75 response was sustained with
treatment through Week 52 in patients randomized to
apremilast at baseline who continued apremilast through the
extension phase (apremilast/apremilast: 52.7%) and in patients
switched from etanercept to apremilast at Week 16 (etanercept/
apremilast: 57.0%) (Table 2). Patients switched from placebo to
apremilast at Week 16 exhibited PASI-75 responses at Week 52
(placebo/apremilast: 53.4%) that were consistent with results in
patients randomized to apremilast at baseline. The non-respon-
der imputation sensitivity analyses demonstrated the following
findings with respect to PASI-75 response at Week 52: placebo/
apremilast (47.9%), apremilast/apremilast (47.3%) and etaner-
cept/apremilast (49.4%) (Table 2).
Improvements in secondary and exploratory endpoints were
generally maintained at Week 52 in apremilast/apremilast
patients and etanercept/apremilast patients (Fig. 5 and
Table 2); responses at Week 52 among placebo/apremilast
patients were generally similar to those in apremilast/apremi-
last patients. This pattern of clinical improvement was
observed through Week 52 for the mean change in DLQI score
(Table 2, LOCF; Fig. 5a, as observed), achievement of DLQI
MCID (Table 2) and achievement of DLQI score of 0 or 1
(Fig. 4). Similarly, at Week 52, improvements in VAS scores
for pruritus (Fig. 5b), skin discomfort/pain and patient global
assessment of psoriasis disease activity (Table 2) as well as



































































Figure 4 Percentage of Patients Achieving a DLQI score of 0 or 1
at Week 16 and Week 52. Based on last-observation-carried-for-
ward analysis for Weeks 16 and 52. DLQI, Dermatology Life Quality
Index.
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Figure 5 (a) Mean Change in DLQI Score. Data represent the
mITT population, as observed at each time point. The vertical lines
indicate two-sided 95% CIs. CI, confidence interval; DLQI, Derma-
tology Life Quality Index. (b) Mean Change in Pruritus VAS Score.
*Mean pruritus VAS scores (0–100 mm, where 0 = no itch at all,
100 = worst itch imaginable) were 62.5 mm (placebo), 62.6 mm
(apremilast) and 57.2 mm (etanercept) at baseline. Data represent
the mITT population, as observed at each time point. The vertical
lines indicate two-sided 95% CIs. VAS, visual analogue scale.
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NAPSI score were sustained in the apremilast/apremilast and
apremilast/etanercept groups (Table 2).
Safety
Placebo-controlled phase: Weeks 0 to 16 A total of 250 ran-
domized patients received ≥1 dose of study medication and were
included in the safety analysis (placebo, n = 84; apremilast,
n = 83; etanercept, n = 83). During the placebo-controlled
phase (Weeks 0 to 16), ≥1 AE was reported in 53.6%, 71.1% and
53.0% of patients receiving placebo, apremilast and etanercept,
respectively (Table 3). Among patients with reported AEs, ≥95%
of AEs were mild or moderate in severity. Severe AEs, serious
AEs and AEs leading to discontinuation were infrequent and
comparable across groups (Table 3). Pneumonia was the only
serious AE that occurred in >1 patient (apremilast, n = 1; etan-
ercept, n = 1). One patient treated with apremilast had commu-
nity-acquired pneumonia and sepsis, although sepsis was never
confirmed; blood culture was negative, and sepsis was consid-
ered secondary to pneumonia. One serious cardiac event charac-
terized as palpitations was reported with apremilast during the
placebo-controlled phase in a patient who had a medical history
of myocardial infarction, anxiety and thyroid disease; the patient
was admitted for observation and managed accordingly and con-
tinued in the study. In addition, one serious cardiac event char-
acterized as complete atrioventricular block was reported in the
etanercept group. No malignancies or serious opportunistic
infections were reported. The most common AEs (in ≥5% of
patients in any treatment group) were nausea, diarrhoea, upper
respiratory tract infection, nasopharyngitis, tension headache
and headache (Table 3). In apremilast-treated patients, more
than half of the reported diarrhoea and nausea cases occurred
within the first 4 weeks of dosing. These were predominantly
mild in severity and generally resolved within 1 month. No
patient in any group reported severe nausea or severe diarrhoea.
Apremilast-extension phase: Weeks 16 to 52 During the
apremilast-extension phase, no increase in the incidence of
common AEs was observed with continued apremilast expo-
sure and no new safety or tolerability issues were observed in
patients who switched from etanercept to apremilast at Week
16. Serious AEs, severe AEs and discontinued treatment due
to AEs remained low (≤2 patients in each group) across all
groups through Week 32. Incidences of common AEs through
Week 32 in the placebo/apremilast, apremilast/apremilast and
etanercept/apremilast groups, respectively, were nausea (4.1%,
2.7%, 6.3%), diarrhoea (16.4%, 4.1%, 7.6%), upper respira-
tory tract infection (1.4%, 5.4%, 0.0%), nasopharyngitis
(0.0%, 1.4%, 3.8%), tension headache (4.1%, 0.0%, 0.0%)
and headache (2.7%, 0.0%, 1.3%). Of note, the incidences of
diarrhoea and nausea were <5.0% in the apremilast/apremilast
group between Weeks 16 and 32. Diarrhoea was more
frequent (16.4%) in placebo patients, who were switched to
apremilast with no titration at Week 16, compared with etan-
ercept patients, who were switched to apremilast with 1 week
of titration (7.6%).
Incidence of common AEs with apremilast remained low
with prolonged apremilast exposure through Week 52 com-
pared with patients who received apremilast during Weeks 0 to
16 (Table 3). Similarly, no new AEs of clinical significance were
observed in the etanercept/apremilast group through Week 52
(Table 3). Serious infection (mastoiditis) was reported in one
(1.4%) patient in the apremilast/apremilast group and psychi-
atric events (psychotic disorder, suicidal ideation) were
reported in one (1.4%) patient in the placebo/apremilast group.
No serious cardiac events or malignancies were reported during
the Weeks 16 to 52 apremilast-extension phase. No cases of
tuberculosis were reported in the study. No clinically meaning-
ful changes in laboratory parameters were reported during the
placebo-controlled phase or the apremilast-extension phase
(Table 3). During the placebo-controlled phase, mean weight
change from baseline was +0.03 kg with placebo, 0.78 kg with
apremilast and +1.10 kg with etanercept. Mean weight change
from baseline was 1.23 kg, 0.63 kg and 0.03 kg in the pla-
cebo/apremilast, apremilast/apremilast and etanercept/apremilast
groups, respectively, during the apremilast-extension period
(Table 4).
Discussion
The results of this study demonstrate that apremilast is an effec-
tive treatment option for biologic-naive patients with moderate-
to-severe plaque psoriasis. The primary endpoint in this study
was met, with a significantly greater proportion of patients trea-
ted with apremilast achieving a PASI-75 response at Week 16 vs.
placebo. The study also demonstrated that etanercept, as com-
pared with placebo, was effective in the treatment of biologic-
naive patients with moderate-to-severe plaque psoriasis. A post
hoc analysis of PASI-75 achievement at Week 16 revealed non-
significant differences between apremilast and etanercept.
Although etanercept-treated patients had a numerically higher
PASI-75 achievement rate than apremilast-treated patients, the
study was not powered to detect such a difference between
groups.
In addition to sustained improvements in PASI-75
response, improvement of psoriasis symptoms (i.e. pruritus
and skin discomfort/pain) and quality of life were observed
as early as Week 2 and were sustained in patients who were
randomized to apremilast at baseline and continued to
receive apremilast through Week 52. Improvements in scalp
psoriasis observed at Week 16 were also maintained through
Week 52 with apremilast. Mean change in NAPSI score con-
tinued to improve in patients who received apremilast
through 52 weeks of treatment. Slower growth of fingernails
may contribute to the lag in observed nail improvements
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compared with improvements in skin, and studies with bio-
logic agents, including etanercept, have demonstrated contin-
ued improvement beyond 6 months.15,16
In this study, most AEs were consistent with the known safety
profiles of apremilast and etanercept. No increase in AEs was
observed with prolonged apremilast exposure in patients who
continued apremilast through Week 52 compared with Weeks 0
to 16. Higher rates of diarrhoea were observed in patients in the
placebo group, who switched to apremilast without titration, vs.
patients who began apremilast dosing with titration. It should be
noted that the prescribing information for apremilast states that
the initial dose of apremilast should be titrated over the first
5 days of administration to reduce risk of gastrointestinal symp-
toms.17,18 No safety signal was detected in serious opportunistic
infections, malignancies and serious cardiac events, consistent
with previous studies.10,11 In addition, no clinically meaningful
changes in laboratory parameters were reported. Analysis of
patients switching from etanercept to apremilast at Week 16
revealed no clinically significant safety findings through Week 52
in this study.
Weight loss has been observed in clinical studies with
apremilast.10,11 Weight gain has been noted with anti-tumour
necrosis factor-a therapies, and it is notable that the weight
gain observed in the etanercept group during the placebo-con-
trolled phase was reversed after patients switched to apremilast
at Week 16. During the long-term apremilast-extension phase,
weight loss did not lead to any overt medical sequelae or
manifestations. In addition, the efficacy achieved with etaner-
cept at Week 16 was generally maintained through Week 52
with apremilast.19
Limitations
This study was not designed to directly compare apremilast and
etanercept, and the comparison of PASI-75 response is limited
by the post hoc nature of the analysis. The hierarchical analysis
of study endpoints also limits the ability to detect differences in
efficacy between the active treatment arms and placebo in some
secondary endpoints. Another potential limitation of the study
was the use of the 50 mg QW dose of etanercept in the active-
controlled arm, which may contribute to an underestimation of
etanercept efficacy. However, it should be noted that a starting
dosage of 50 mg QW has been shown to be efficacious in
patients with moderate-to-severe plaque psoriasis20 and is con-
sistent with some dosing recommendations for etanercept.21,22 A
study investigating dosage patterns of etanercept during the first
year of treatment for psoriasis in a general managed-care popu-
lation using a US claims database found that the starting dose of
etanercept varied, and that up to one-quarter of patients
(25.8%) initiated etanercept at 50 mg QW.23 Additionally, the
ability to administer injections once weekly during scheduled
study office visits to maintain the blinding of patients and physi-
cians contributed to the selection of the 50 mg QW dose for the
LIBERATE study.
Patients receiving etanercept transitioned to apremilast
regardless of clinical response, which may not reflect real-world
clinical scenarios; clinically, switching would likely be predicated
on poor clinical response or safety findings. The results cannot
be generalized to non-plaque forms of psoriasis.
Conclusions
Apremilast and etanercept significantly reduced the severity of
moderate-to-severe plaque psoriasis over 16 weeks in biologic-
naive patients. Improvements were generally sustained through
Week 52 in patients who continued apremilast at Week 16 across
a range of endpoints, including patient-reported outcomes, that
contribute significantly to patients’ disease severity and quality
of life. Apremilast demonstrated an acceptable safety profile
through Week 52, with no need for extensive laboratory moni-
toring. In addition, switching from etanercept to apremilast was
well tolerated with no new safety findings; efficacy was generally
Table 4 Weight assessments during the placebo-controlled phase (Weeks 0 to 16) and the apremilast-extension phase (Weeks 16 to 52)
Bodyweight assessments








































































*n/m, the number of patients with ≥1 occurrence at any time point/number of patients with ≥1 post-baseline value.
†No dose titration for apremilast.
‡Dose titration for apremilast.
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maintained through Week 52 with apremilast. The findings from
LIBERATE demonstrate that oral apremilast is an effective thera-
peutic option for the treatment of biologic-naive patients with
moderate-to-severe plaque psoriasis and provide important
safety information for clinicians regarding switching from a bio-
logic therapy.
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